|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fluid therapy for severe acute pancreatitis in acute response stage显示文摘为严重尖锐胰腺炎(树液) 的背景液体治疗不应该仅仅解决血体积的缺乏,而且在尖锐反应舞台阻止液体隐遁。最新,在那里,为液体治疗的策略没奉献给树液。那么,这研究被瞄准在树液的预后上调查液体治疗治疗的效果。76 个病人在 72 小时树液发作以内根据标准有希望地被招收的方法。他们随机被分到一个快速的液体扩大组(组我, n=36 ) 并且一个控制液体扩大组(组, n=40 ) 。血液动力学的混乱快速是任何一个(液体注入率是 10-15 ml 吗?? | MAO En-qiang TANG Yao-qing FEI Jian QIN Shuai WU Jun LI Lei MIN Dong ZHANG Sheng-dao | 2009 | Chinese Medical Journal2009，，2： | 89 |
| 2 | Towards 6G wireless communication networks:vision,enabling technologies,and new paradigm shifts显示文摘The fifth generation(5G)wireless communication networks are being deployed worldwide from 2020 and more capabilities are in the process of being standardized,such as mass connectivity,ultra-reliability,and guaranteed low latency.However,5G will not meet all requirements of the future in 2030 and beyond,and sixth generation(6G)wireless communication networks are expected to provide global coverage,enhanced spectral/energy/cost efficiency,better intelligence level and security,etc.To meet these requirements,6G networks will rely on new enabling technologies,i.e.,air interface and transmission technologies and novel network architecture,such as waveform design,multiple access,channel coding schemes,multi-antenna technologies,network slicing,cell-free architecture,and cloud/fog/edge computing.Our vision on 6G is that it will have four new paradigm shifts.First,to satisfy the requirement of global coverage,6G will not be limited to terrestrial communication networks,which will need to be complemented with non-terrestrial networks such as satellite and unmanned aerial vehicle(UAV)communication networks,thus achieving a space-airground-sea integrated communication network.Second,all spectra will be fully explored to further increase data rates and connection density,including the sub-6GHz,millimeter wave(mmWave),terahertz(THz),and optical frequency bands.Third,facing the big datasets generated by the use of extremely heterogeneous networks,diverse communication scenarios,large numbers of antennas,wide bandwidths,and new service requirements,6G networks will enable a new range of smart applications with the aid of artificial intelligence(AI)and big data technologies.Fourth,network security will have to be strengthened when developing 6G networks.This article provides a comprehensive survey of recent advances and future trends in these four aspects.Clearly,6G with additional technical requirements beyond those of 5G will enable faster and further communications to the extent that the boundary between physical and cyber worlds disappears. | Xiaohu YOU Cheng-Xiang WANG Jie HUANG Xiqi GAO Zaichen ZHANG Mao WANG Yongming HUANG Chuan ZHANG Yanxiang JIANG Jiaheng WANG Min ZHU Bin SHENG Dongming WANG Zhiwen PAN Pengcheng ZHU Yang YANG Zening LIU Ping ZHANG Xiaofeng TAO Shaoqian LI Zhi CHEN Xinying MA Chih-Lin I Shuangfeng HAN Ke LI Chengkang PAN Zhimin ZHENG Lajos HANZO Xuemin(Sherman)SHEN Yingjie Jay GUO Zhiguo DING Harald HAAS Wen TONG Peiying ZHU Ganghua YANG Jun WANG Erik GLARSSON Hien Quoc NGO Wei HONG Haiming WANG Debin HOU Jixin CHEN Zhe CHEN Zhangcheng HAO Geoffrey Ye LI Rahim TAFAZOLLI Yue GAO HVincent POOR Gerhard P.FETTWEIS Ying-Chang LIANG | 2021 | Science China(Information Sciences)2021，64，1： | 122 |
| 3 | Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2——Guangdong Province,China,May-June 2021显示文摘On May 21,2021,a local case of coronavirus disease 2019(COVID-19)was confirmed in a 75-year-old woman(experienced onset of symptoms on May 18)in Liwan District,Guangzhou City,Guangdong Province,China.The number of infections has increased in the following 10 days and led to 5 generations of transmission. | Meng Zhang Jianpeng Xiao Aiping Deng Yingtao Zhang Yali Zhuang Ting Hu Jiansen Li Hongwei Tu Bosheng Li Yan Zhou Jun Yuan Lei Luo Zimian Liang Youzhi Huang Guoqiang Ye Mingwei Cai Gongli Li Bo Yang Bin Xu Ximing Huang Yazun Cui Dongsheng Ren Yanping Zhang Min Kang Yan Li | 2021 | China CDC weekly2021，3，27： | 51 |
| 4 | A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients显示文摘Background Stents are widely used in China but the clinical impression is somehow that restenosis is less common because of the lower prevalence of coronary artery disease (CAD) and associated risk factors in Chinese populations. However, no large-sample published studies are available on angiographic stent restenosis including those of bare-metal stent (BMS) or drug-eluting stent (DES) in Chinese Han ethnic population. Mothods A total of 1633 consecutive patients with CAD who had undergone coronary stenting, quantitative coronary angiography (QCA) were retrospectively studied. At the time of stent implantation and at 7 months post-stenting 675 patients had a follow-up angiography. Statistical analysis was made with the chi-square test for categorical variables, unpaired t test for continuous variables, univariate or multivariate regression for baseline and angiographic characteristics and the Kaplan-Meier method for rate of target lesion revascularization (TLR). Results Stent restenosis was defined as ≥50% diameter stenosis in the dilated segment. A total of 675 patients with 1074 lesions were subjected to angiographic follow-up for 7 months on average. Of these lesions, 448 were implanted with BMS whereas 626 lesions with DES. At 7 months, bare-metal in-stent restenosis occured in 148 lesions (33.0%), and bare metal in-segment restenosis in 155 lesions (34.6%) in contrast to drug-eluting in-stent restenosis in 48 lesions (7.7%) and drug-eluting in-segment restenosis in 73 lesions (11.7%) (P<0.001 compared with BMS respectively). Late loss in both in-stent and in segment was higher in BMS than in DES groups [(1.00±0.69) vs (0.28±0.52); (0.78±0.71) vs (0.21±0.52), P<0.001 respectively]. Angulated lesion, lesion length, pre-procedural minimal luminal diameter (MLD), and BMS were independent predictors for TLR, (P<0.01 respectively), whereas current smoker, ostial lesion, and stent overlapping, post-procedure in-stent MLD, lesion length, and stent types were independent predictors for in-segment restenosis (P<0.01 respectively). Standard coronary risk factors such as hypertension, hyperlipidemia, diabetes, and history of CAD were not associated with a higher rate of restenosis caused by BMS or DES implantation in our Chinese Han ethnic population. Conclusions Coronary stenting including BMS or DES implantation in Chinese Han ethnic patients is associated with a restenosis rate comparable to that demonstrated in previous studies from the western countries, and predictors of stent restenosis are somehow different from those in the western population. | XU Bo LI Jian-jun YANG Yue-jin MA Wei-hua CHEN Ji-lin QIAO Shu-bin QIN Xue-wen YAO Min LIU Hai-bo WU Yong-jian YUAN Jin-qing CHEN Jue YOU Shi-jie DAI Jun XIA Ran GAO Run-lin | 2006 | Chinese Medical Journal2006，，7： | 23 |
| 5 | A novel gene delivery system targeting cells expressing VEGF receptors显示文摘Two ligand oligopeptides GV1 and GV2 were designed according to the putative binding region of VEGF to its receptors. GV1, GV2 and endosome releasing oligopeptide HA20 were conjugated with poly-L-lysine or protamine and the resulting conjugates could interact with DNA in a noncovalent bond to form a complex. Using pSV2-β-galactosidase as a reporter gene, it has been demonstrated that exogenous gene was transferred into bovine aortic arch-derived endothelial cells (ABAE) andhuman malignant melanoma cell lines (A375) in vitro. In vivo experiments, exogenous gene was transferred into tumor vascular endothelial cells and tumor cells of subcutaneously transplanted human colon cancer LOVO, human malignant melanoma A375 and human hepatoma graft in nude mice. This system could also target gene to intrahepatically transplanted human hepatoma injected via portal vein in nude mice. These results are correlated with theGene delivery system targeting VEGF receptors relevant receptors (flt-1, flk-1/KDR) expression on the targeted cells and tissues. | LI JUN MIN JUN SONG HAN YI HUANG PEI KUN TIAN SHU MIN QU MIN YAO HUI QIU JIANG DA FANG WAN JING CHU LUO CHENG XIAO GU JIAN REN GU( National Labomtory for Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai 200032,China)(National Laboratory of | 1999 | Cell Research1999，9，1： | 22 |
| 6 | Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study显示文摘Background:5-Fluorouracil(5-FU)and capecitabine-associated cardiotoxicity ranging from asymptomatic electro-cardiography(ECG)abnormalities to severe myocardial infarction has been reported in a number of studies,but such cardiotoxicity in Chinese patients with malignant diseases has not been investigated to date.In the present study,we aimed to prospectively evaluate the incidence rates and clinical manifestations of 5-FU-and capecitabine-associated cardiotoxicity in cancer patients recruited from multiple centers in China.Methods:Among the 527 patients who completed the study,196 received 5-FU-based chemotherapy and 331 received capecitabine-based chemotherapy as either first-line or adjuvant therapy.Adverse events were reported during the treatment and up to 28 days of follow-up.Outcome measures included ECG,myocardial enzymes,cardiac troponin,brain natriuretic peptide and echocardiography.Univariate analysis and logistic regression were performed for subgroup analysis and identification of significant independent variables that are associated with cardiotoxicity of both agents.Results:In total,161 of 527 patients(30.6%)experienced cardiotoxicity.The incidence rate of cardiotoxicity was 33.8%(112/331)in the capecitabine group,which was significantly higher than the rate of 25%(49/196)in the 5-FU group(P=0.0042).110/527 patients(20.9%)suffered arrhythmia,105/527(19.9%)developed ischemic changes,while only 20/527 patients(3.8%)presented heart failure and 6/527 patients(1.1%)had myocardial infarction.Pre-existing cardiac disease,hypertension,capecitabine-based chemotherapy and duration of treatment were identified as sig-nificant risk factors associated with cardiotoxicity.The odds ratio were 15.7(prior history of cardiac disease versus no history),1.86(capecitabine versus 5-FU),1.06(5-8 versus 1-4 chemotherapy cycles)and 1.58(hypertension versus no hypertension),respectively.Conclusions:Cardiotoxicity induced by fluoropyrimidines in the Chinese population may be underestimated in clini-cal practice.Close monitoring of patients is recommended,especially for those patients at high risk for cardiotoxicity.Possible risk factors are duration of treatment,capecitabine-based chemotherapy,pre-existing cardiac diseases and hypertension.Trial registration This study was initiated on January 22,2014 and has been retrospectively registered with the registra-tion number ChiCTR1800015434 . | Jianjun Peng Chao Dong Chang Wang Weihua Li Hao Yu Min Zhang Qun Zhao Bo Zhu Jun Zhang Wenliang Li Fenghua Wang Qiong Wu Wenhao Zhou Ying Yuan Meng Qiu Gong Chen | 2018 | Cancer Communications2018，38，1： | 23 |
| 7 | Association between Vitamin D Insufficiency and the Risk for Gestational Diabetes Mellitus in Pregnant Chinese Women显示文摘Objective To investigate the association between vitamin D deficiency and risk of gestational diabetes mellitus(GDM) in pregnant Chinese women.Methods A nested case-control study was conducted.Clinical and biochemical data were analyzed for 200 subjects with GDM and 200 subjects with normal glucose tolerance(NGT).Results The median(interquartile range) serum 25-hydroxyvitamin D(25OHD) levels were 22.39(17.67,29.38) and 25.86(19.09,34.88) nmol/L in the GDM and NGT groups,respectively.Rates of 25OHD deficiency or insufficiency were significantly higher in the GDM group than in the NGT group.Subjects with 25OHD levels <25 nmol/L had a 1.8-fold higher risk of GDM compared with subjects with higher vitamin D levels.In the GDM group,serum 25OHD was independently associated with HbA1c and insulin resistance after adjusting for confounding factors.In the NGT group,serum 25OHD was independently associated with fasting plasma glucose and systolic blood pressure after adjusting for maternal age and other confounding factors.Conclusion 25OHD insufficiency is very common in Chinese women.Low 25OHD status may be associated with insulin resistance and act as a risk factor for GDM. | WANG Ou NIE Min HU Ying Ying ZHANG Kui LI Wei PING Fan LIU Jun Tao CHEN Li Meng XING Xiao Ping | 2012 | Biomedical and Environmental Sciences2012，25，4： | 21 |
| 8 | Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis显示文摘Background:Psoriasis is a chronic inflammatory skin disease,affecting about 0.6%of the Chinese population.Many patients are not well controlled by conventional treatments,thus there is need for new treatment regimens.In this study,we assessed the efficacy and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis.Methods:This study was a 52-week,multicentre,randomized,double-blind,placebo-controlled,parallel-group,Phase 3 trial.A sub-population of study participants(≥18 years)of Chinese ethnicity were randomized to receive subcutaneous injections of 300 or 150 mg secukinumab,or placebo.The co-primary endpoints were psoriasis area severity index(PASI)75 and Investigator’s Global Assessment(IGA)0/1 at Week 12.Results:A total of 441 Chinese patients were enrolled in this study.Co-primary outcomes were achieved;300 and 150 mg secukinumab were superior to placebo as shown in the proportion of patients that achieved PASI 75(97.7%and 87.2%vs.3.7%,respectively;P<0.001),and IGA 0/1(82.3%and 69.7%vs.2.7%;P<0.001)at Week 12.Treatment efficacy was maintained until Week 52.There was no increase in overall adverse events with secukinumab relative to placebo throughout the 52-week period.Conclusion:Secukinumab is highly effective and well tolerated in Chinese patients with moderate to severe plaque psoriasis. | Lin Cai Jian-Zhong Zhang Xu Yao Jun Gu Quan-Zhong Liu Min Zheng Shi-Fa Zhang Jin-Hua Xu Cheng-Xin Li Hao Cheng Qing Guo Wei-Li Pan Shen-Qiu Li Ruo-Yu Li Zai-Pei Guo Zhi-Qi Song Shan-Shan Li Xiu-Qin Dong Linda Wang Rong Fu Pascaline Regnault Pascal Charef Ratal Mazur Manmath Patekar | 2020 | Chinese Medical Journal2020，，22： | 21 |
| 9 | Expression of regulating apoptosis gene and apoptosis index in primary liver cancer显示文摘INTRODUCTIONProgramed cell death plays an important role in thegenesis of cancer.Certain cancer genes canregulate apoptosis.Recently,several proteins thatare structurally related to Bcl-2,an inhibitor ofapoptosis,have been identified.Therefore,novel strategies and agents that target specificmolecular pathways,as well as triggering a | Hong Yu Xu You Lin Yang Xi Li Guan Guang Song Ai Min Jiang Li Jun Shi | 2000 | World Journal of Gastroenterology2000，6，5： | 21 |
| 10 | Traditional Chinese medicine integrated with chemotherapy for stage Ⅳ non-surgical gastric cancer: a retrospective clinical analysis显示文摘OBJECTIVE: Traditional Chinese medicine(TCM) is regarded as an important treatment for gastric cancer patients, especially for those in advanced stage. To evaluate the effects of TCM treatment on gastric cancer patients, the authors performed a retrospective study to report the result of the integrated treatment of TCM with chemotherapy for stage IV non-surgical gastric cancer.METHODS: In this study, 182 patients with stage IV and non-surgical gastric cancer were retrospectively analyzed to evaluate the effects of TCM integrated with chemotherapy. Among the 182 cases, 88 cases received integrated therapy consisting of TCM and chemotherapy, while 94 cases received chemotherapy alone. The overall survival and Karnofsky performance status(KPS) score were measured as the main outcome.RESULTS: The median overall survival of the integrated therapy group and chemotherapy group were 16.9 and 10.5 months, respectively. The 1-, 3-and 5-year survival rates of integrated therapy group vs. chemotherapy group were 70% vs. 32%, 18% vs. 4%, and 11% vs. 0%, respectively. There was a significant difference between the two groups(χ2 = 42.244, P < 0.001). After six-month treatment, KPS scores of the integrated therapy group and the chemotherapy group were 75.00 ± 14.78 and 60.64 ± 21.39, respectively(P < 0.001). The Cox regression analysis showed that TCM treatment is a protective factor for patients' overall survival. CONCLUSION: This study demonstrated that TCM integrated with chemotherapy may prolong overall survival and improve survival rate and life quality of patients with stage IV non-surgical gastric cancer. | xuan liu li-juan xiu jian-peng jiao jing zhao ying zhao ye lu jun shi yong-jin li min ye yu-fang gu xiao-wei wang jing-yu xu ci-an zhang yong-ying liu yun luo xiao-qiang yue | 2017 | Journal of Integrative Medicine2017，15，6： | 18 |
| 11 | Genotyping for Kidd, Kell, Duffy, Scianna, and RHCE blood group antigens polymorphisms in Jiangsu Chinese Han显示文摘 | LIU Zhong ZENG Rong CHEN Qing LI Min SHI Guang-yao WEI Peng HUANG Cheng-yin TANG Rong-cai SUN Jun ZHANG Xue-guang | 2012 | Chinese Medical Journal2012，，6： | 18 |
| 12 | Angiographic prevalence of myocardial bridging in a defined very large number of Chinese patients with chest pain显示文摘背景:心肌内冠的动脉被称为的 epicardial 分割的肌纤维 overlying 心肌的衔接(MB ) 。MB 的可变流行与小、大的样品尺寸研究在尸体和 angiographic 系列被描述了。另外,没有类似的学习在中国人口被报导。这研究的目的是调查 MB 的 angiographic 流行在连续有从我们的中心的胸痛的 37,106 个中国病人。方法:我们进行了观察研究在经历的病人之中与 MB 评估连续案例选择冠的血管造影术,并且在很大的样品尺寸的这研究分析了 angiograhic 流行和 MB 的临床的特征。结果:在有胸痛的 37 105 个病人之中,我们以一种回顾的方式与 1011 MB 发现了 1002 个案例,并且全面流行是 2.70% 。尽管(991/1002 ) 超过 99% 病人有单个桥牌, 8 个案例被发现有超过二 MB (七与二,和一与三) 。没有动脉粥样硬化患者损害,总的来说 54.39% 案例(545/1002 ) 有 MB,并且(973/1011 )96.24% 在左前面的下降冠的动脉(男孩) 衔接定位了,主要在男孩的中间(792/1011, 78.33%) 。根据诺贝尔分类,单个桥(n=991 ) ,阻塞的 <50% 是占优势的(471/991, 47.52%) 。完全, 50%-69% 占了 34.81%(345/991 ) ,阻塞的 >70% 是 17.65%(175/991 ) 。结论:这些数据证明在有胸痛的中国病人的 angiographically 可检测的 MB 的流行类似于以前的研究的那些,与在这种很大的样品尺寸的 2.7% 流行。 | LI Jian-jun SHANG Zheng-lu YAO Min LI Jie YANG Yue-jin CHEN Ji-lin QIAO Shu-bin MA Wei-hua QIN Xue-wen LIU Hai-bo WU Yong-jian YUAN Jin-qing CHEN Jue YOU Shi-jie DAI Jun XU Bo XIA Ran GAO Run-lin | 2008 | Chinese Medical Journal2008，，5： | 17 |
| 13 | Role of plasma C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting显示文摘背景血浆的角色高敏感在 in-stent 狭窄(ISR ) 的 C 反应的蛋白质(hs-CRP ) 仍然保持争论。我们在成功的冠的 stenting 以后与稳定的咽峡炎( SA )在病人在承认和后续调查了血浆 hs-CRP 水平以便为我们总结了的 ISR.Methods 澄清 hs-CRP 的预兆的价值有冠的 drug-eluting stent ( DES )的 303 个连续长期的 SA 病人 implantation.The ISR 被量的冠的分析分析( QCA )在一个平均数, 8 个月的后续,和病人作为 ISR 组( n=48 )和 non-ISR g 根据检测 ISR 被划分成二个组血浆 hs-CRP 在所有病人,在承认和 8 月的后续被检验在整个调查 period.Results QCA 继续的标准药介绍了那 48 个病人(15.8%) 在后续受不了 ISR。当血浆 hs-CRP 在在承认和后续的 non-ISR 组比那在 ISR 组是更高的时,基本临床的特征在二个组之间是类似的, P 0.001 分别地。 Multivariate 回归分析显示在承认或后续的那血浆 hs-CRP 水平能独立地预言 ISR 出现( OR=5.581 ,95% Cl 2.532-12.302 , P0.001and OR=6.299 ,95% CI 2.722-14.577 , P 0.001 ,分别地) .Conclusions 我们的数据显示那血浆 hs-CRP 水平可以独立地与冠的 DES 培植在 SA 病人在承认和后续预言 ISR ,它暗示长期的、持续全身的煽动性的回答可能涉及 ISR | XU Yan-lu LI Jian-jun XU Bo ZHU Cheng-gang YANG Yue-jin CHEN Ji-lin QIAO Shu-bin YUAN Jin-qing QIN Xue-wen MA Wei-hua YAO Min LIU Hai-bo WU Yong-jian CHEN Jue YOU Shi-jie DAI Jun XIA Ran GAO Run-lin | 2011 | Chinese Medical Journal2011，，6： | 17 |
| 14 | Daclatasvir plus asunaprevir in treatment-na?ve patients with hepatitis C virus genotype 1b infection显示文摘AIM To assess daclatasvir plus asunaprevir(d UAL) in treatment-na?ve patients from China's Mainland, Russia and South Korea with hepatitis C virus(HCV) genotype 1 b infection. METHODS Patients were randomly assigned(3:1) to receive 24 wk of treatment with d UAL(daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily) beginning on day 1 of the treatment period(immediate treatment arm) or following 12 wk of matching placebo(placebodeferred treatment arm). The primary endpoint was a comparison of sustained virologic response at posttreatment week 12(SVR12) compared with the historical SVR rate for peg-interferon plus ribavirin(70%) among patients in the immediate treatment arm. The first 12 wk of the study were blinded. Safety was assessed in d UAL-treated patients compared with placebo patients during the first 12 wk(doubleblind phase), and during 24 wk of d UAL in both arms combined.RESULTS In total, 207 patients were randomly assigned to immediate(n = 155) or placebo-deferred(n = 52) treatment. Most patients were Asian(86%), female(59%) and aged < 65 years(90%). Among them, 13% had cirrhosis, 32% had IL28 B non-CC genotypes and 53% had baseline HCV RNA levels of ≥ 6 million IU/m L. Among patients in the immediate treatment arm, SVR12 was achieved by 92%(95% confidence interval: 87.2-96.0), which was significantly higher than the historical comparator rate(70%). SVR12 was largely unaffected by cirrhosis(89%), age ≥ 65 years(92%), male sex(90%), baseline HCV RNA ≥ 6 million(89%) or IL28 B non-CC genotypes(96%), although SVR12 was higher among patients without(96%) than among those with(53%) baseline NS5 A resistanceassociated polymorphisms(at L31 or Y93 H). during the double-blind phase, aminotransferase elevations were more common among placebo recipients than among patients receiving d UAL. during 24 wk of d UAL therapy(combined arms), the most common adverse events(≥ 10%) were elevated alanine aminotransferase and upper respiratory tract infection; emergent grade 3-4 laboratory abnormalities were infrequently observed, and all grade 3-4 aminotransferase abnormalities(alanine aminotransferase, n = 9; aspartate transaminase, n = 6) reversed within 8-11 d. Two patients discontinued d UAL treatment; one due to aminotransferase elevations, nausea, and jaundice and the other due to a fatal adverse event unrelated to treatment. There were no treatment-related deaths.CONCLUSION d UAL was well-tolerated during this phase 3 study, and SVR12 with d UAL treatment(92%) exceeded thehistorical SVR rate for peg-interferon plus ribavirin of 70%. | Lai Wei Fu-Sheng Wang Ming-Xiang Zhang Ji-Dong Jia Alexey A Yakovlev Wen Xie Eduard Burnevich Jun-Qi Niu Yong Jin Jung Xiang-Jun Jiang Min Xu Xin-Yue Chen Qing Xie Jun Li Jin-Lin Hou Hong Tang Xiao-guang Dou Yash Gandhi Wen-Hua Hu Fiona McPhee Stephanie Noviello Michelle Treitel Ling Mo Jun Deng | 2018 | World Journal of Gastroenterology2018，24，12： | 17 |
| 15 | Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting显示文摘背景尽管在预言动脉粥样硬化患者损害的快速的前进的 C 反应的蛋白质(CRP ) 的角色强烈地在不稳定的冠的动脉疾病被学习了,从有稳定的咽峡炎(SA ) 的病人的数据大部分是不在的。现在的学习评估了一个中间尺寸的耐心的队与 stent 培植和后续经历了经皮的冠的干预(一种总线标准)冠的 angiography ( CAG )并且测试了高度敏感的 CRP 的那增加的血浆水平将显示的假设 de novo 非目标的快速的前进在有 SA.Methods 的中国病人的冠的动脉损害学习人口与长期的 SA 311 个连续病人包括了在起始的承认上经历了冠的 stent | XU Yan-lu LI Jian-jun XU Bo ZHU Cheng-gang YANG Yue-jin CHEN Ji-lin QIAO Shu-bing YUAN Jin-qing QIN Xue-wen MA Wei-hua YAO Min LIU Hai-bo WU Yong-jian CHEN Jue YOU Shi-jie DAI Jun XIA Ran GAO Run-lin | 2011 | Chinese Medical Journal2011，，19： | 17 |
| 16 | Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol显示文摘Menopause is associated with dyslipidemia and an increased risk of cardio-cerebrovascular disease.The classic view assumes that the underlying mechanism of dyslipidemia is attributed to an insufficiency of estrogen.In addition to a decrease in estrogen, circulating follicle-stimulating hormone (FSH)levels become elevated at menopause.In this study,we find that blocking FSH reduces serum cholesterol via inhibiting hepatic cholesterol biosynthesis.First,epidemiological results show that the serum FSH levels are positively correlated with the serum total cholesterol levels,even after adjustment by considering the effects of serum estrogen,in addition,the prevalence of hypercholesterolemia is significantly higher in peri-menopausal women than that in premenopausal women.Furthermore,we generated a mouse model of FSH elevation by intraperitoneally injecting exogenous FSH into ovariectomized (OVX)mice,in which a normal level of estrogen (E2)was maintained by exogenous supplementation. Consistently,the results indicate that FSH,independent of estrogen,increases the serum cholesterol level in this mouse model. Moreover,blocking FSH signaling by anti-FSHβ antibody or ablating the FSH receptor (FSHR)gene could effectively prevent hypercholesterolemia induced by FSH injection or high-cholesterol diet feeding.Mechanistically,FSH,via binding to hepatic FSHRs, activates the Gi2α/β-arrestin-2/Akt pathway and subsequently inhibits the binding of FoxO1 with the SREBP-2 promoter,thus preventing FoxO1 from repressing SREBP-2 gene transcription.This effect,in turn,results in the upregulation of SREBP-2,which drives HMGCR nascent transcription and de novo cholesterol biosynthesis,leading to the increase of cholesterol accumulation.This study uncovers that blocking FSH signaling might be a new strategy for treating hypercholesterolemia during menopause, particularly for women in peri-menopause characterized by FSH elevation only. | Yanjing Guo Meng Zhao Tao Bo Shizhan Ma Zhongshang Yuan Wenbin Chen Zhao He Xu Hou Jun Liu Zhenhai Zhang Qiang Zhu Qiangxiu Wang Xiaoyan Lin Zhongli Yang Min Cui Lu Liu Yujie Li Chunxiao Yu Xiaoyi Qi Qian Wang Haiqing Zhang Qingbo Guan Lifang Zhao Shimeng Xuan Huili Yan Yanliang Lin Li Wang Qihang Li Yongfeng Song Ling Gao Jiajun Zhao | 2019 | Cell Research2019，29，2： | 16 |
| 17 | Plasmacytoid Dendritic Cell Function and Cytokine Network Profiles in Patients with Acute or Chronic Hepatitis B Virus Infection显示文摘 | Ming-Hui Li Lu Zhang Dan Zhang Wei-Hua Cao Tian-Lin Qi Hong-Xiao Hao Xing-Yue Wang Chong-Ping Ran Xiao-Jing Qu Shun-Ai Liu Yao Lu Ge Shen Shu-Ling Wu Min Chang Ru-Yu Liu Lei-Ping Hu Wen-Hao Hua Gang Wan Jun Cheng Yao Xie | 2018 | Chinese Medical Journal2018，，1： | 16 |
| 18 | THE SIMULATION OF THE SAR IMAGE OF INTERNAL SOLITARY WAVES IN ALBORAN SEA显示文摘SAR imaging mechanism of internal wave is studied. The numerical modelling of internal waves is obtained by the two level scheme. The simulaed SAR images that have better expressed the features of internal waves are given by the internal waves SAR imaging theory and numerical modelling result. | Meng Jun min Ocean University of Qingdao, Qingdao 266003, China Zhang Zi li, Zhao Jun sheng First Institute of Oceanography, State Oceanic Administration, Qingdao 266061, China Zhang Jie Key Laboratory of Marine Science and Numerical Modelling, | 2001 | Journal of Hydrodynamics2001，13，3： | 16 |
| 19 | Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing显示文摘单个房间的定序是为描出的一个强大的工具为个性化的癌症管理的同种细胞的关系和识别关键司机基因。这里,我们执行了结肠癌的一个盒子的单个房间的定序的分析。人口遗传分析在肿瘤房间人口识别了二独立克隆。主要肿瘤克隆作为早 oncogenic 事件怀有 APC 和 TP53 变化,而次要的克隆包含了优势的 CDC27 和 PABPC1 变化。在这二克隆的次要的克隆支持的 APC 和 TP53 变化的缺席从二细胞的起源被导出。体的变化等位基因频率系列的检查另外 21 个整个织物的定序 exome 的盒子在结肠癌揭示了同种细胞的起源的异质。下次,我们识别了在单个房间的水平显示出变化的高频率,但是在人口水平展出了低流行的变异的基因 SLC12A5。变异的 SLC12A5 的功能的描述在结肠癌揭示了它的潜在的 oncogenic 效果。我们的学习在单个房间的水平支持提供第一条 exome 宽的证据那结肠癌能具有 biclonal 起源,并且建议在一个队的低流行的变化可以也在单个水平起重要 protumorigenic 作用。 | Chang Yu Jun Yu Xlaotlan Yao Wllham KK Wu Youyong Lu Senwel Tang Xiangchun Li Li Bao Xiaoxing Li Yong Hou Renhua Wu Min Jian Ruoyan Chen Fan Zhang Lixia Xu Fan Fan Jun He Qiaoyi Liang Hongyi Wang Xueda Hu Minghui He Xiang Zhang Hancheng Zheng Qibin Li Hanjie Wu Yan Chen Xu Yang Shida Zhu Xun Xu Huanming Yang Jian Wang Xiuqing Zhang Joseph JY Sung Yingrui Li Jun Wang | 2014 | Cell Research2014，，6： | 16 |
| 20 | A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a “real world” setting:six-month follow-up results显示文摘背景几临床的试用证明了 rapamycin-eluting stents 显著地在经皮的冠的干预(一种总线标准) 以后减少狭窄的风险。鲜艳的小鸟 stent 和 Excel stent (与 bioabsorbable 聚合物涂) rapamycin-eluting stents 的二种不同类型在中国被做,两个最近被州的食物药品管理局在中国为临床的使用同意了。然而,是否在在在2006年6月的每日的 practice.Methods 的 stents 的二种类型之间的安全和功效地有差别,是不清楚的, 190 个连续病人的一个总数专门与鲜艳的小鸟 stents 被对待( n=93 ,鲜艳的小鸟组)或胜过 stents ( n=97 ,胜过组)在我们的中心并且在这研究被包括。主要不利心脏的事件的频率(向,一死亡,心肌的梗塞或目标损害 revascularization 合成) ,二进制狭窄,和迟了的腔损失和 stent 血栓在二个 groups.Results 病人之间在一个六月的后续时期期间被比较,损害特征在这些组之间是可比较的。主要不利心脏的事件率在医院里并且在 6 个月是低的(2.1% 在 Excel 组织, 0% 在鲜艳的小鸟组织, P 0.05 ) 。6 月的 angiographic in-stent 狭窄率在两个组是 0% ,与联系迟了的损失(0.15 更高显著地在 PES 组织((0.14 ???????琠牨浯潢祬楳 吗?? | LIU Hai-bo XU Bo QIAO Shu-bin YANG Yue-jin MA Wei-hua QIN Xue-wen YAO Min WU Yong-jian YUAN Jin-qing CHEN Jue YOU Shi-jie DAI Jun XIA Ran LI Jian-jun CHEN Ji-lin GAO Run-lin | 2007 | Chinese Medical Journal2007，，7： | 15 |
您所在的机构暂未开通此部分的功能，请联系管理员